Joanna Johnson, MD
Pediatric Medicine · Philadelphia, PANPI 1689638116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $813 and has fallen 60.4% since, to $322 in 2024.
Across 82 payments — averaging $28.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$336
- AstraZeneca$332
- Biocryst US Sales Co., LLC$265
- GSK$246
- CSL Behring$215
- Boehringer Ingelheim$134
- plus $813 from 17 others
What the payments were for
- Food & beverage$2,340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 9 | $336 |
| AstraZeneca(2 entities) | 8 | $332 |
| Biocryst US Sales Co., LLC | 7 | $265 |
| GSK | 11 | $246 |
| CSL Behring | 7 | $215 |
| Boehringer Ingelheim | 5 | $134 |
| Optinose US, Inc. | 1 | $119 |
| Amgen | 4 | $113 |
| Bayer | 6 | $103 |
| Blueprint Medicines Corporation | 3 | $91 |
| Octapharma USA, Inc. | 3 | $62 |
| Novo Nordisk | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Acclarent, Inc | 1 | $38 |
| Kaleo, Inc. | 2 | $36 |
| Alk-abello, Inc | 2 | $30 |
| Incyte Corporation | 2 | $28 |
| Pfizer | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| LEO Pharma Inc. | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Covis Pharma GmbH | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 15 | $269 |
| Fluticasone Propionate | 15 | $134 |
| Montelukast Sodium | 12 | $113 |
Paid to pharmacies, not to this prescriber.
Other pediatric medicine in Philadelphia
- John RuffinPhiladelphia$0
- John BratschPhiladelphia$0
- Janelle Brown BratschPhiladelphia$0
- Daniel KietzPittsburgh$0
- William GianfagnaPottsville$0
- Andrew PeckhamDanville$0
- Alexis MatarangasMilton$0
- Michael FreemanHershey$0
- Kaitlin OstranderPittsburgh$0
- Barry SpectorLititz$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.